dc.contributor.author |
Van den Berg, Sylvia
|
|
dc.contributor.author |
Van Rooyen, Cathy
|
|
dc.contributor.author |
Wessels, Pieter Frederik
|
|
dc.contributor.author |
Brauer, Marieke
|
|
dc.contributor.author |
Green, Robin J.
|
|
dc.date.accessioned |
2023-05-23T05:02:41Z |
|
dc.date.available |
2023-05-23T05:02:41Z |
|
dc.date.issued |
2022-03 |
|
dc.description.abstract |
Patients rely on healthcare providers as their most credible and frequent source of vaccine information. It is therefore crucial that healthcare providers are informed and have evidence-based, objective and clear guidance on vaccine efficacy and specific adverse events following immunisation (AEFI). Reported serious AEFIs are extremely rare for the COVID-19 vaccines. This article discusses the main AEFIs attributed to COVID-19 vaccines, including neurological complications of Guillain-Barré syndrome (GBS) and acute transverse myelitis (ATM), thrombosis; cardiac complications, including myocarditis, pericarditis and cardiomyopathy; and allergic reactions such as anaphylaxis, urticaria and skin rashes. The benefits of COVID-19 vaccination outweigh the risks; however, it is important that healthcare providers are aware of the risks and know how to recognise and manage them. |
en_US |
dc.description.department |
Paediatrics and Child Health |
en_US |
dc.description.librarian |
am2023 |
en_US |
dc.description.uri |
https://journals.co.za/journal/caci |
en_US |
dc.identifier.citation |
Van den Berga, S., Van Rooyen, C., Wessels, P.F. et al. 2022, 'COVID-19 vaccines : adverse events following immunisation', Current Allergy and Clinical Immunology, vol. 35, no. 1, pp. 16-22, doi : 10.520/ejc-caci-v35-n1-a3. |
en_US |
dc.identifier.issn |
1609-3607 (print) |
|
dc.identifier.other |
10.520/ejc-caci-v35-n1-a3 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/90777 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Allergy Society of South Africa |
en_US |
dc.rights |
© Allergy Society of South Africa. |
en_US |
dc.subject |
COVID-19 vaccine |
en_US |
dc.subject |
Adverse events |
en_US |
dc.subject |
Guillain-Barré syndrome (GBS) |
en_US |
dc.subject |
Acute transverse myelitis (ATM) |
en_US |
dc.subject |
Thrombosis |
en_US |
dc.subject |
Cardiac complications |
en_US |
dc.subject |
Myocarditis |
en_US |
dc.subject |
Pericarditis |
en_US |
dc.subject |
Cardiomyopathy |
en_US |
dc.subject |
Vaccine allergy |
en_US |
dc.subject |
Urticarial |
en_US |
dc.subject |
Skin rash |
en_US |
dc.subject |
COVID-19 pandemic |
en_US |
dc.subject |
Coronavirus disease 2019 (COVID-19) |
en_US |
dc.title |
COVID-19 vaccines : adverse events following immunisation |
en_US |
dc.type |
Article |
en_US |